307 related articles for article (PubMed ID: 32768244)
1. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.
Regev A; Avigan MI; Kiazand A; Vierling JM; Lewis JH; Omokaro SO; Di Bisceglie AM; Fontana RJ; Bonkovsky HL; Freston JW; Uetrecht JP; Miller ED; Pehlivanov ND; Haque SA; Harrison MJ; Kullak-Ublick GA; Li H; Patel NN; Patwardhan M; Price KD; Watkins PB; Chalasani NP
J Autoimmun; 2020 Nov; 114():102514. PubMed ID: 32768244
[TBL] [Abstract][Full Text] [Related]
2. Deciphering the Dynamic Complexities of the Liver Microenvironment - Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI).
Wang T; Yeh MM; Avigan MI; Pelosof L; Feldman GM
AAPS J; 2021 Aug; 23(5):99. PubMed ID: 34401948
[TBL] [Abstract][Full Text] [Related]
3. Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.
Regev A; Palmer M; Avigan MI; Dimick-Santos L; Treem WR; Marcinak JF; Seekins D; Krishna G; Anania FA; Freston JW; Lewis JH; Sanyal AJ; Chalasani N
Aliment Pharmacol Ther; 2019 Mar; 49(6):702-713. PubMed ID: 30761572
[TBL] [Abstract][Full Text] [Related]
4. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.
Palmer M; Regev A; Lindor K; Avigan MI; Dimick-Santos L; Treem W; Marcinak JF; Lewis JH; Anania FA; Seekins D; Shneider BL; Chalasani N
Aliment Pharmacol Ther; 2020 Jan; 51(1):90-109. PubMed ID: 31762074
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and management of immune mediated liver injury from checkpoint inhibitors.
Likhitsup A; Fontana RJ
Curr Opin Gastroenterol; 2024 May; 40(3):164-171. PubMed ID: 38375823
[TBL] [Abstract][Full Text] [Related]
6. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation.
Peeraphatdit TB; Wang J; Odenwald MA; Hu S; Hart J; Charlton MR
Hepatology; 2020 Jul; 72(1):315-329. PubMed ID: 32167613
[TBL] [Abstract][Full Text] [Related]
7. Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology.
Hercun J; Vincent C; Bilodeau M; Lapierre P
Front Immunol; 2022; 13():907591. PubMed ID: 35844534
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and pathological characteristics of immune-mediated liver injury caused by immune checkpoint inhibitors].
Zeng YL; Li Y; Tang H; Xu Y; Chen MJ; Li Y; Wang MZ; Tan B; Qian JM
Zhonghua Nei Ke Za Zhi; 2023 Jun; 62(6):700-704. PubMed ID: 37263954
[No Abstract] [Full Text] [Related]
9. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience.
da Silva JA; Falcão D; Cardoso C; Pires AL; Araújo A; Castro-Poças F
Ann Hepatol; 2021 Dec; 26():100561. PubMed ID: 34653687
[TBL] [Abstract][Full Text] [Related]
10. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.
Treem WR; Palmer M; Lonjon-Domanec I; Seekins D; Dimick-Santos L; Avigan MI; Marcinak JF; Dash A; Regev A; Maller E; Patwardhan M; Lewis JH; Rockey DC; Di Bisceglie AM; Freston JW; Andrade RJ; Chalasani N
Drug Saf; 2021 Feb; 44(2):133-165. PubMed ID: 33141341
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System.
Wang H; Yang H; Zhou X; Zhang X
Clin Ther; 2023 Feb; 45(2):151-159. PubMed ID: 36682994
[TBL] [Abstract][Full Text] [Related]
12. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies.
Mizuno K; Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Kawashima H; Inukai Y; Toyoda H; Yokota K; Hase T; Maeda O; Kiyoi H; Nagino M; Hibi H; Kodera Y; Fujimoto Y; Sone M; Gotoh M; Ando Y; Akiyama M; Hasegawa Y; Fujishiro M
J Gastroenterol; 2020 Jun; 55(6):653-661. PubMed ID: 32124082
[TBL] [Abstract][Full Text] [Related]
13. Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers.
Yamamoto A; Yano Y; Ueda Y; Yasutomi E; Hatazawa Y; Hayashi H; Yoshida R; Asaji N; Shiomi Y; Tobimatsu K; Sakai A; Kodama Y
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1747-1756. PubMed ID: 33222015
[TBL] [Abstract][Full Text] [Related]
14. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents.
Suzman DL; Pelosof L; Rosenberg A; Avigan MI
Liver Int; 2018 Jun; 38(6):976-987. PubMed ID: 29603856
[TBL] [Abstract][Full Text] [Related]
15. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study.
Chan SL; Yip TC; Wong VW; Tse YK; Yuen BW; Luk HW; Lui RN; Chan HL; Mok TS; Wong GL
Cancer Med; 2020 Oct; 9(19):7052-7061. PubMed ID: 32780516
[TBL] [Abstract][Full Text] [Related]
16. Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor.
Sawada K; Hayashi H; Nakajima S; Hasebe T; Fujiya M; Okumura T
J Gastroenterol Hepatol; 2020 Jun; 35(6):1042-1048. PubMed ID: 31752049
[TBL] [Abstract][Full Text] [Related]
17. Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors.
Shojaie L; Bogdanov JM; Alavifard H; Mohamed MG; Baktash A; Ali M; Mahov S; Murray S; Kanel GC; Liu ZX; Ito F; In GK; Merchant A; Stohl W; Dara L
Cell Death Dis; 2024 Feb; 15(2):140. PubMed ID: 38355725
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of immunosuppressant use for the treatment of immune checkpoint inhibitor-induced liver injury: A systematic review and meta-analysis.
Chen K; He J; Xu J; Chen J
Front Oncol; 2023; 13():1088741. PubMed ID: 37035152
[TBL] [Abstract][Full Text] [Related]
19. Causality assessment for suspected DILI during clinical phases of drug development.
Regev A; Seeff LB; Merz M; Ormarsdottir S; Aithal GP; Gallivan J; Watkins PB
Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S47-56. PubMed ID: 25352327
[TBL] [Abstract][Full Text] [Related]
20. Drug induced liver injury: an update.
Garcia-Cortes M; Robles-Diaz M; Stephens C; Ortega-Alonso A; Lucena MI; Andrade RJ
Arch Toxicol; 2020 Oct; 94(10):3381-3407. PubMed ID: 32852569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
